---
title: Optimisation of Solute Removal and Water Usage in Paediatric Haemodialysis
nct_id: NCT07466459
overall_status: ENROLLING_BY_INVITATION
phase: NA
sponsor: University Hospital, Ghent
study_type: INTERVENTIONAL
primary_condition: Pediatric
countries: Belgium
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07466459.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07466459"
ct_last_update_post_date: 2026-03-12
last_seen_at: "2026-05-12T06:58:23.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Optimisation of Solute Removal and Water Usage in Paediatric Haemodialysis

**NCT ID:** [NCT07466459](https://clinicaltrials.gov/study/NCT07466459)

## Key Facts

- **Status:** ENROLLING_BY_INVITATION
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 10
- **Lead Sponsor:** University Hospital, Ghent
- **Conditions:** Pediatric, Efficiency, Hemodialysis Patient, Hemodialysis Treatment
- **Start Date:** 2025-11-13
- **Completion Date:** 2026-12-31
- **CT.gov Last Update:** 2026-03-12

## Brief Summary

Children receiving chronic haemodialysis are typically treated with dialysis machines designed for adult patients. As a result, some devices do not allow the ideal blood or dialysate flow rates to be set for paediatric use. In addition, the optimal dialysate-to-blood flow ratio for maximising solute removal while minimising water consumption remains poorly defined.

The aim of this study is to quantify the dialyser extraction ratio and clearance across different dialysis modalities and a range of dialysate-to-blood flow ratios. Blood and dialysate samples are collected at the blood inlet, blood outlet, and dialysate outlet lines, and concentrations of various uraemic toxins-spanning a range of molecular weights-are measured to calculate solute clearances.

## Detailed Description

Children undergoing haemodialysis are enrolled in the study. During a mid-week dialysis session, three dialysis modalities are applied sequentially for 10-15 minutes each: haemodialysis (HD), predilution haemodiafiltration (pre-HDF), and postdilution haemodiafiltration (post-HDF). For each modality, the dialysate-to-blood flow ratio is adjusted to approximately 1.0, 1.5, and 2.0.

For each setting, blood samples are collected from the blood inlet and outlet lines, and dialysate samples are taken from the spent dialysate line. All sampling is performed within the first hour of the dialysis session.

All samples are analysed for a range of uraemic toxins, including small water-soluble solutes, middle molecules, and protein-bound toxins. Using inlet and outlet blood concentrations, the extraction ratio is calculated for each setting. Based on the dialysate flow rate, total water usage for a full dialysis session is estimated. Together, these calculations allow determination of the optimal dialysate-to-blood flow ratio that provides the highest dialyser clearance with the lowest relative water consumption.

## Eligibility

- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* not older than 18 years old
* at least three months of stable hemodialysis

Exclusion Criteria:

* a non well-functioning vascular access
* infections at the study week
```

## Arms

- **dialysis settings** (EXPERIMENTAL) — In each participant and in a consecutive way, different dialysis modalities and dialysate to blood flow ratios are set.

## Interventions

- **blood and dialysate sampling** (OTHER) — For ach setting, blood and dialysate samples are taken in order to be able to calculate the extraction ratio and dialyser clearance.

## Primary Outcomes

- **Extraction Ratio** _(time frame: During the first hour of one midweek dialysis session, different dialysis flows and modalities are set for the time needed to take the samples.)_ — Extraction ratio is calculated from dialyzer inlet and outlet toxin concentrations for different dialysis settings.

Dialysis efficiency, based on extration ratio, is related to the corresponding water usage.

## Locations (1)

- Ghent University Hospital, Nephrology, Ghent, Belgium

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ghent university hospital, nephrology|ghent||belgium` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07466459.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07466459*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*